Kyowa Hakko Kirin

Kyowa Hakko Kirin

CA - La Jolla
Biotechnology
WebsiteLinkedInCareers Page

Focus: Platform Drug Discovery Technology

Kyowa Hakko Kirin is a life sciences company focused on Platform Drug Discovery Technology.

OncologyNeurologyGastroenterologyHematologyNephrology
Employees
5000+
Open Jobs
0

Products & Portfolio (3)

1 discontinued product not shown

CRYSVITA
burosumab
Peak
mAbINJECTION · INJECTABLE
X-linked hypophosphatemia is caused by excess fibroblast growth factor 23 (FGF23) which suppresses renal tubular phosphate reabsorption and the renal production of 1,25 dihydroxy vitamin D. Burosumab-twza binds to and inhibits the biological activity of FGF23 restoring renal phosphate reabsorption and increasing the serum concentration of 1,25 dihydroxy vitamin D.
X-linked hypophosphatemia (XLH) in adultolderFGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors+1 more
2018
30
NOURIANZ
istradefylline
LOE Approaching
ORAL · TABLET
Parkinson's disease is unknown. In in vitro studies and in in vivo animal studies, istradefylline was demonstrated to be an adenosine A 2A receptor antagonist.
2019
15
POTELIGEO
mogamulizumab-kpkc
Peak
mAbINJECTION · INJECTABLE
Chemokine Receptor Type 4 Interactions
2018
30

Pipeline & Clinical Trials

Treatment algorithm for OIC
Opioid-induced Constipation
N/A
Clinical Trials (1)
NCT04404933Study of Opioid-Induced Constipation 2 Project
N/A
Clinical assessment
Opioid-induced Constipation
N/A
Clinical Trials (1)
NCT04350112Study of Opioid-Induced Constipation 1 Project
N/A
N/A
Clinical Trials (1)
NCT04321694Expanded Access for KHK2455
N/A
N/A
Clinical Trials (1)
NCT04946409Burden of Disease and Functional Impairment in XLH
N/A
N/A
Clinical Trials (1)
NCT03651505X-linked Hypophosphatemia Disease Monitoring Program
N/A
Phase 1
Clinical Trials (1)
NCT06266299A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1
Phase 1
Clinical Trials (5)
NCT02526160Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Phase 3
NCT03703102Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
Phase 2
NCT02647866Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Phase 2

+2 more

Istradefylline
Drug Abuse
Phase 1
Clinical Trials (1)
NCT02609477A Study to Evaluate Abuse Potential of Istradefylline
Phase 1
Phase 1
Clinical Trials (1)
NCT02127476A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease
Phase 1
Mogamulizumab-Kpkc
Mycosis Fungoides
Phase 1
Clinical Trials (1)
NCT06235281Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
Phase 1
Phase 1
Clinical Trials (1)
NCT00938288A Study of KW-3357 in Congenital Antithrombin Deficiency
Phase 1
Phase 1
Clinical Trials (1)
NCT00921336Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor
Phase 1
KHK2866
Neoplasms
Phase 1
Clinical Trials (1)
NCT01279291Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1
KW-2450 in combination with lapatinib and letrozole
Breast Cancer
Phase 1
Clinical Trials (1)
NCT01199367Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
Phase 1
Istradefylline
Hepatic Impairment
Phase 1
Clinical Trials (1)
NCT02256033Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline
Phase 1
Istradefylline 40 mg
Parkinson's Disease
Phase 1
Clinical Trials (1)
NCT02174250The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
Phase 1
KRN1493
Healthy
Phase 1
Clinical Trials (1)
NCT00952094Pharmacokinetic, Pharmacodynamic and Safety Evaluation After Single Oral Administration of KRN1493
Phase 1
Phase 1
Clinical Trials (1)
NCT00775502Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Phase 1
Phase 1
Clinical Trials (1)
NCT01582399Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240
Phase 1
Phase 1
Clinical Trials (1)
NCT07192471A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Phase 1
Phase 1
Clinical Trials (1)
NCT02181699Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 1
CEP-37250/KHK2804
Solid Tumour
Phase 1
Phase 1
Clinical Trials (1)
NCT03915405KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT04190654Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
Phase 1
Sancuso - Part 1
Healthy Volunteers
Phase 1
Clinical Trials (1)
NCT05027646Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
Phase 1
Phase 1
Clinical Trials (1)
NCT00346632An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Phase 1
Phase 1
Clinical Trials (1)
NCT04147910Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356
Phase 1
Phase 1
Clinical Trials (1)
NCT00457782A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Phase 1
Phase 1/2
Clinical Trials (1)
NCT01063907A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2
Phase 1/2
Clinical Trials (5)
NCT04745234Mogamulizumab Q4week Dosing in Participants With R/R CTCL
Phase 2
NCT05996185Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Phase 2
NCT02705105Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Phase 1/2

+2 more

Phase 1/2
Clinical Trials (1)
NCT00199342A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT06525636A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
Phase 1/2
Phase 1/2
Clinical Trials (5)
NCT02537431Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Phase 3
NCT02750618Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
Phase 2
NCT02312687Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Phase 2

+2 more

Phase 1/2
Clinical Trials (1)
NCT00888927Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Phase 1/2
Phase 1/2
Clinical Trials (2)
NCT00838578Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase 1/2
NCT00575562Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Phase 1
Zandelisib
CLL
Phase 2
Clinical Trials (1)
NCT05209308Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
Phase 2
Phase 2
Clinical Trials (3)
NCT01728805Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Phase 3
NCT01626664KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Phase 2
NCT01226472Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Phase 2
Phase 2
Clinical Trials (1)
NCT01780844A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
Phase 2
Granisetron
Gastroparesis
Phase 2
Clinical Trials (1)
NCT04501211Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis
Phase 2
Phase 2
Clinical Trials (1)
NCT02921789Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
Phase 2
Phase 2
Clinical Trials (1)
NCT01611142Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Phase 2
Istradefylline 40 mg
Idiopathic Parkinson's Disease
Phase 3
Clinical Trials (1)
NCT01968031A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Phase 3
Istradefylline
Parkinson's Disease
Phase 3
Clinical Trials (1)
NCT00199368An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
Phase 3
Phase 3
Clinical Trials (1)
NCT02915705Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
Phase 3
Phase 3
Clinical Trials (1)
NCT04695860Anti-FGF23 (Burosumab) in Adult Patients With XLH
Phase 3
Istradefylline
Parkinson's Disease
Phase 3
Clinical Trials (5)
NCT05885360Istradefylline Effect Protocol on Parkinson's Disease Tremor
Phase 4
NCT00199381An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
Phase 3
NCT00199394A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
Phase 3

+2 more

Phase 3
Clinical Trials (1)
NCT04745832Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Phase 3
Istradefylline 20 mg or 40 mg
Idiopathic Parkinson's Disease
Phase 3
Clinical Trials (1)
NCT02610231Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 4 approved products, 81 clinical trials
Top TAs: Oncology, Neurology, Gastroenterology
Publications: 25 in PubMed
Portfolio Health
Peak2 (50%)
LOE Approaching2 (50%)
4 total products
Therapeutic Area Focus
Oncology
2 marketed33 pipeline
Neurology
16 pipeline
Immunology
3 pipeline
Nephrology
3 pipeline
Hematology
1 marketed
Marketed
Pipeline